Eli Lilly yesterday announced the decision to stop ... This decision to cease ongoing Phase III development of the schizophrenia treatment is expected to result in a third-quarter charge to ...

Eli Lilly has reportedly commenced Phase III clinical trials of oral medication, orforglipron, for weight loss in India. The ...

Eli Lilly and Company’s LLY stock has risen 21.1% in six months compared with an increase of 10.5% for the industry. The ...

The trial compares Eli Lilly’s lutetium zadavotide guraxetan with Astellas’s Xtandi (enzalutamide) or Janssen’s Zytiga ...

The late-stage clinical trial results showed that Eli Lilly’s once-weekly insulin efsitora matched daily injections for ...

The race is on to develop the first daily weight-loss pill that would be both cheaper and less invasive than the current ...

BioAge will use the proceeds from the initial public offering to move its oral apelin receptor agonist azelaprag past its ...

Eli Lilly has released detailed results from the Phase III QWINT-2 and QWINT-5 trial showing that its once weekly insulin efsitora (efsitora alfa) demonstrated a similar reduction in HbA1C levels ...

The endorsement follows Eli Lilly's announcement of successful Phase III trial results for its once-weekly insulin efsitora, which is seen as a strong competitor to Novo Nordisk (NYSE:NVO)'s icodec.

Neoadjuvant therapy is an essential part of high-risk stage III resectable melanoma management, with combination ...

The endorsement follows Eli Lilly's announcement of successful Phase III trial results for its once-weekly insulin efsitora, which is seen as a strong competitor to Novo Nordisk (NYSE:NVO)'s icodec.